Literature DB >> 32282876

Surgical treatment of pulmonary metastases in the Netherlands: data from the Dutch Lung Cancer Audit for Surgery.

Martijn van Dorp1, Naomi Beck2,3, Willem Hans Steup4, Wilhelmina Hendrika Schreurs1.   

Abstract

OBJECTIVES: Surgical resection is widely employed as a potential curative treatment option for patients with limited lung metastases originating from a wide range of primary tumours. However, there are no clear national or international practice guidelines and, thereby, the risk for potential practice variation exists. This study aims to define the current practice for the surgical treatment of pulmonary metastases in the Netherlands by using data from the Dutch Lung Cancer Audit for Surgery (DLCA-S).
METHODS: Data from the DLCA-S were used to analyse patients undergoing a parenchymal lung resection for the treatment of pulmonary metastases between 2012 and 2017. Volume of metastasectomies per hospital was calculated as a proportion of the volume of primary lung cancer resection. Studied outcomes were overall complications and postoperative mortality and complicated course. For the latter, both the national average and between-hospital variation were calculated.
RESULTS: A total of 2090 patients, distributed over 45 Dutch hospitals, were included for analysis. The most common primary cancer was colorectal carcinoma (N = 1087, 52.0%) followed by the urogenital carcinoma (N = 296, 14.2%). The most common type of parenchymal resection was a wedge resection (N = 1477, 70.7%) followed by a lobectomy (N = 424, 20.3%). Resection was performed minimally invasively in 1548 patients (74.1%) with a conversion rate of 3.8%. Resection of a solitary metastasis was performed in 1663 patients (79.6%). In 40 patients (1.9%), 4 or more metastases were resected. A postoperative complicated course was noted in 3.6%, and the 30-day mortality rate was 0.7%. The variety between hospitals in the volume of metastasectomies in proportion to the volume of primary lung cancer resections was 3.4-41.5%.
CONCLUSIONS: This analysis of the DLCA-S registry provides a unique insight into current practice on pulmonary metastasectomies in the Netherlands over a 6-year period. The rate of postoperative adverse outcome was limited, and the morbidity and mortality were lower compared to primary lung cancer resections in the DLCA-S database.
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Database; Lung resection; Pulmonary metastasectomy; Pulmonary metastases; VATS

Mesh:

Year:  2020        PMID: 32282876     DOI: 10.1093/ejcts/ezaa090

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  4 in total

Review 1.  Management of single pulmonary metastases from colorectal cancer: State of the art.

Authors:  Marco Chiappetta; Lisa Salvatore; Maria Teresa Congedo; Maria Bensi; Viola De Luca; Leonardo Petracca Ciavarella; Floriana Camarda; Jessica Evangelista; Vincenzo Valentini; Giampaolo Tortora; Stefano Margaritora; Filippo Lococo
Journal:  World J Gastrointest Oncol       Date:  2022-04-15

2.  Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) randomized controlled trial: a systematic review of published responses.

Authors:  Norman R Williams; Hannah Patrick; Francesca Fiorentino; Alexander Allen; Manuj Sharma; Mišel Milošević; Fergus Macbeth; Tom Treasure
Journal:  Eur J Cardiothorac Surg       Date:  2022-06-15       Impact factor: 4.534

Review 3.  Impact of the extent of lung resection on postoperative outcomes of pulmonary metastasectomy for colorectal cancer metastases: an exploratory systematic review.

Authors:  Elena Prisciandaro; Laurens J Ceulemans; Dirk E Van Raemdonck; Herbert Decaluwé; Paul De Leyn; Luca Bertolaccini
Journal:  J Thorac Dis       Date:  2022-07       Impact factor: 3.005

4.  Novel strategy to treat lung metastases: Hybrid therapy involving surgery and radiofrequency ablation.

Authors:  Takaaki Hasegawa; Hiroaki Kuroda; Noriaki Sakakura; Yozo Sato; Shohei Chatani; Shinichi Murata; Hidekazu Yamaura; Takeo Nakada; Yuko Oya; Yoshitaka Inaba
Journal:  Thorac Cancer       Date:  2021-06-09       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.